Developer docs
API playgroundTry for free, no card

Search company profiles

Medannex

Full company profile

uuid000327f

Namestring
Medannex
Websiteurl
medannex.org
Company typeenum
Private
Founded yearint
2009
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biopharmaceutical drug development, pediatric oncology therapeutics, annexin-A1 targeted therapy, osteosarcoma drug candidate, preclinical cancer research
Industry1 code
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Pediatric Oncology Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medannex is developing MDX-124, a first-in-class drug candidate targeting annexin-A1 for the treatment of pediatric osteosarcoma, a rare childhood bone cancer. The therapy is being advanced toward clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Targeted improvement in survival rates among children with osteosarcoma
Product overview1 text field

Medannex is a biopharmaceutical company developing MDX-124, a first-in-class drug candidate targeting pediatric osteosarcoma. The company is advancing this therapy toward clinical trials with support from an Innovate UK grant, building on prior evaluation in adult cancer studies.

Product and service1 record
1MDX-124
CategoryOncology Drug Candidate
Description

First-in-class drug candidate targeting annexin-A1, being developed as a novel treatment for pediatric osteosarcoma, a rare childhood bone cancer. The candidate is being prepared for clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Y-mAbs is a commercial-stage biopharmaceutical company developing antibody-based therapeutics for pediatric cancers. It is highly comparable to Medannex in target patient population (children with cancer) and oncology focus, though at a more advanced stage with marketed products.

TypeDirect peer
Description

Day One Biopharmaceuticals is a clinical-stage company specifically focused on developing targeted therapies for pediatric cancers and rare diseases of childhood. Its mission, patient focus, and stage are directly aligned with Medannex's pediatric osteosarcoma program.

TypeDirect peer
Description

Salarius develops treatments for rare pediatric cancers including Ewing sarcoma, another childhood bone/soft-tissue cancer with similar biology and patient population to osteosarcoma. Both companies target underserved pediatric sarcomas.

TypeDirect peer
Description

Kazia Therapeutics develops oncology therapies with a particular focus on pediatric brain cancers (diffuse midline gliomas). It is a directly comparable small-cap, single-indication pediatric oncology biotech with similar funding scale.

TypeDirect peer
Description

Oncternal develops oncology therapies for rare and difficult-to-treat cancers, including Ewing sarcoma. Its rare-pediatric-cancer focus and small-cap, single-asset profile closely mirror Medannex's positioning.

TypeDirect peer
Description

Marker Therapeutics is a clinical-stage immuno-oncology company with programs in both adult and pediatric cancers, including sarcoma indications. Comparable as a small oncology biotech targeting cancer through novel mechanisms.

TypeDirect peer
Description

Cyclacel develops small-molecule medicines for cancer, with historical emphasis on pediatric and rare leukemias. Comparable as a small-cap, clinical-stage oncology biotech focused on underserved indications.

TypeBroad incumbent
Description

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. While larger and with a broader pipeline, it operates in the same oncology drug development space with novel mechanisms.

TypeBroad incumbent
Description

Deciphera is a commercial-stage oncology company developing kinase inhibitors for cancer treatment. Comparable as an established oncology drug developer with a focus on targeted therapies, though at a more advanced stage and broader portfolio.

TypeBroad incumbent
Description

BioMarin is a global rare disease biopharmaceutical company with a portfolio of approved therapies for serious and life-threatening conditions, including pediatric indications. Relevant as an established leader in rare pediatric disease drug development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medannex

Pediatric Oncology Therapeuticsmedannex.org

Medannex firmographics

Firmographics
Name
Medannex
Website
https://medannex.org
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Medannex industry classification

Industry
Product category
Pediatric Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Biopharmaceutical drug development
  • Pediatric oncology therapeutics
  • Annexin-A1 targeted therapy
  • Osteosarcoma drug candidate
  • Preclinical cancer research

Where Medannex is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Markets served

Medannex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Medannex product offering

Product offering

Core offering

Medannex is developing MDX-124, a first-in-class drug candidate targeting annexin-A1 for the treatment of pediatric osteosarcoma, a rare childhood bone cancer. The therapy is being advanced toward clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.

Product overview

Medannex is a biopharmaceutical company developing MDX-124, a first-in-class drug candidate targeting pediatric osteosarcoma. The company is advancing this therapy toward clinical trials with support from an Innovate UK grant, building on prior evaluation in adult cancer studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • MDX-124 First-in-class drug candidate targeting annexin-A1, being developed as a novel treatment for pediatric osteosarcoma, a rare childhood bone cancer. The candidate is being prepared for clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.

Quantifiable outcome

  • Targeted improvement in survival rates among children with osteosarcoma

Companies that use Medannex

Customer profile

Segments1 record

Ideal customer profiles1 record

Medannex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Medannex partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Medannex competitors and assessment

Company assessment

Direct peers

  • Y-mAbs Therapeutics: Y-mAbs is a commercial-stage biopharmaceutical company developing antibody-based therapeutics for pediatric cancers. It is highly comparable to Medannex in target patient population (children with cancer) and oncology focus, though at a more advanced stage with marketed products.
  • Day One Biopharmaceuticals: Day One Biopharmaceuticals is a clinical-stage company specifically focused on developing targeted therapies for pediatric cancers and rare diseases of childhood. Its mission, patient focus, and stage are directly aligned with Medannex's pediatric osteosarcoma program.
  • Salarius Pharmaceuticals: Salarius develops treatments for rare pediatric cancers including Ewing sarcoma, another childhood bone/soft-tissue cancer with similar biology and patient population to osteosarcoma. Both companies target underserved pediatric sarcomas.
  • Kazia Therapeutics: Kazia Therapeutics develops oncology therapies with a particular focus on pediatric brain cancers (diffuse midline gliomas). It is a directly comparable small-cap, single-indication pediatric oncology biotech with similar funding scale.
  • Oncternal Therapeutics: Oncternal develops oncology therapies for rare and difficult-to-treat cancers, including Ewing sarcoma. Its rare-pediatric-cancer focus and small-cap, single-asset profile closely mirror Medannex's positioning.
  • Marker Therapeutics: Marker Therapeutics is a clinical-stage immuno-oncology company with programs in both adult and pediatric cancers, including sarcoma indications. Comparable as a small oncology biotech targeting cancer through novel mechanisms.
  • Cyclacel Pharmaceuticals: Cyclacel develops small-molecule medicines for cancer, with historical emphasis on pediatric and rare leukemias. Comparable as a small-cap, clinical-stage oncology biotech focused on underserved indications.

Broad incumbents

  • MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. While larger and with a broader pipeline, it operates in the same oncology drug development space with novel mechanisms.
  • Deciphera Pharmaceuticals: Deciphera is a commercial-stage oncology company developing kinase inhibitors for cancer treatment. Comparable as an established oncology drug developer with a focus on targeted therapies, though at a more advanced stage and broader portfolio.
  • BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with a portfolio of approved therapies for serious and life-threatening conditions, including pediatric indications. Relevant as an established leader in rare pediatric disease drug development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

Medannex social profiles

Digital presence

Medannex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medannex leadership team

Management profile

Number of profiles

Profiles2 records

Medannex funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medannex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medannex

What does Medannex do?

Medannex is developing MDX-124, a first-in-class drug candidate targeting annexin-A1 for the treatment of pediatric osteosarcoma, a rare childhood bone cancer. The therapy is being advanced toward clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.

Is Medannex a public or private company?

Medannex is a private company. It is classified as venture growth investor backed and is currently operating.

When was Medannex founded?

Medannex was founded in 2009. It employs 11 to 50 people.

Where is Medannex based?

Medannex is headquartered in Edinburgh, United Kingdom, in the Europe region.

Who are Medannex's main competitors?

Direct peers on record are Y-mAbs Therapeutics, Day One Biopharmaceuticals, Salarius Pharmaceuticals, Kazia Therapeutics, Oncternal Therapeutics, Marker Therapeutics and Cyclacel Pharmaceuticals. Broad incumbents are MacroGenics, Deciphera Pharmaceuticals and BioMarin Pharmaceutical.

Does Medannex have an API?

No public API is recorded for Medannex.

What industry is Medannex in?

Medannex's product category is Pediatric Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals